Vallerie V. McLaughlin, MD
Professor of Internal Medicine, Division of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Aryeh Fischer, MD
Associate Professor of Medicine
Division of Rheumatology
University of Colorado Denver
Interstitial Lung Disease Program
National Jewish Health
Michael A. Mathier, MD
Assistant Professor of Medicine
Director, Pulmonary Hypertension Program
Associate Director, Cardiovascular Fellowship Program
University of Pittsburgh
Mobile + Online on RealCME
Pulmonary arterial hypertension (PAH) is a rare, devastating, progressive disorder characterized by high blood pressure in the pulmonary arteries. Early symptoms of PAH include dyspnea, dizziness and fatigue. In later stages, PAH often leads to severe disability and death. A rapid pace of development has led to new insight into diagnostic approaches and treatment options for PAH. The primary goal of this continuing education activity is to enhance competency and build additional skills among clinicians in the management of advanced PAH.
. Target Audience
This activity is designed for cardiologists, critical care physicians, pulmonologists, and other clinicians interested in PAH.
Upon completion of this educational activity, the participant should be able to:
Follow guideline recommendations for use of multiple diagnostic tests to accurately diagnosis PAH.
Compare the risks and benefits of PAH therapeutic options for individual patients.
Select preferred treatment options based on guidelines for the most critically ill patients with PAH.
Outline current evidence regarding combination treatment approaches for patients with PAH.
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee, disclose all significant financial interest with commercial interests.
Sciences, Inc.; and United Therapeutics Corporation. She served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; United Therapeutics Corporation. She has received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; United Therapeutics Corporation.
Dr. Fischer discloses that he has received grant support from Gilead Sciences, and has served as a consultant and on the advisory board for Actelion Pharmaceuticals Ltd.
Dr. Mathier discloses that he has served as a consultant for Actelion Pharmaceuticals Ltd., Gilead Sciences, and United Therapeutics, and has received grant funding from Actelion Pharmaceuticals Ltd. and Forest Pharmaceuticals, Inc.
Dr. Harold Nelson (independent reviewer) discloses he is a consultant for Merck, Shionogi, and Pearl Pharmaceuticals, and an investigator for Lincoln Diagnostics, Rigel, and Circassia.
All other activity planners and reviewers have no conflicts of interest to disclose. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of National Jewish Health and MCM Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.
National Jewish Health designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR PARTICIPATING IN THIS ACTIVITY AND OBTAINING CME CREDIT
There are no fees for participating in and receiving CME credit for this online educational activity. By reviewing the course content and successfully completing the post-test and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the post-test and activity evaluation
• Clinicians who successfully complete the post-test and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 80% correct
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation
Commercial Support Statements
This activity was supported by unrestricted educational grants from Actelion Pharmaceuticals Ltd. and United Therapeutics Corporation.
National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.